Homepage
Healthcare · Biotechnology · United States · Updated May 11, 2:43am
$2.74
Price
$172.2M
Market Cap
44
Employees
1.43
Beta
Thomas Civik
CEO
Business Description
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-2.14
Stock Price: $2.74
EPS (Diluted): -1.28
EPS (Diluted): -1.28
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
1.34
Stock Price: $2.74
Total Equity: $53.41M
Shares: 62,143,166
Total Equity: $53.41M
Shares: 62,143,166
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-0.94
Market Cap: $172.16M
Total Debt: $18.67M
Cash: $15.42M
EBITDA: -$79.91M
Total Debt: $18.67M
Cash: $15.42M
EBITDA: -$79.91M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$74.7M
Market Cap: $172.16M
Total Debt: $18.67M
Cash: $15.42M
Total Debt: $18.67M
Cash: $15.42M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
82.8%
Gross Profit: $11.47M
Revenue: $13.86M
Revenue: $13.86M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-609.2%
Operating Income: -$84.42M
Revenue: $13.86M
Revenue: $13.86M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-574.5%
Net Income: -$79.62M
Revenue: $13.86M
Revenue: $13.86M
ROE (Profit from shareholder equity)
CALCNet Income / Total Equity
-149.1%
Net Income: -$79.62M
Total Equity: $53.41M
Total Equity: $53.41M
ROIC (Profit from all invested capital)
CALCNOPAT / Invested Capital
-151.6%
Operating Income: -$84.42M
Tax Rate: -1.8%
Equity: $53.41M
Total Debt: $18.67M
Cash: $15.42M
Tax Rate: -1.8%
Equity: $53.41M
Total Debt: $18.67M
Cash: $15.42M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
3.41
Current Assets: $72.11M
Current Liabilities: $21.13M
Current Liabilities: $21.13M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.35
Short-Term Debt: $1.69M
Long-Term Debt: $16.98M
Total Debt: $18.67M
Total Equity: $53.41M
Long-Term Debt: $16.98M
Total Debt: $18.67M
Total Equity: $53.41M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.22
Revenue: $13.86M
Shares: 62,143,166
Shares: 62,143,166
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$0.86
Total Equity: $53.41M
Shares: 62,143,166
Shares: 62,143,166
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-1.02
Operating CF: -$63.50M
CapEx: -$9,000
Shares: 62,143,166
CapEx: -$9,000
Shares: 62,143,166
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $2.74
Stock Price: $2.74
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$79.62M
Net Income: -$79.62M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares PYXS against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $16.1M | $13.9M |
| Cost of Revenue | $0 | $0 | $0 | $475,000 | $2.4M |
| Gross Profit | $0 | $0 | $0 | $15.7M | $11.5M |
| Operating Expenses | $69.7M | $123.5M | $82.2M | $105.1M | $95.9M |
| Operating Income | -$69.7M | -$123.5M | -$82.2M | -$89.5M | -$84.4M |
| Net Income | -$76.0M | -$120.7M | -$73.8M | -$77.3M | -$79.6M |
| EBITDA | -$69.1M | -$122.8M | -$80.3M | -$65.5M | -$79.9M |
| EPS | $-2.53 | $-3.57 | $-1.85 | $-1.32 | $-1.28 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $274.7M | $179.3M | $9.7M | $19.5M | $15.4M |
| Total Current Assets | $278.7M | $186.6M | $124.6M | $132.4M | $72.1M |
| Total Assets | $280.0M | $211.4M | $173.7M | $157.2M | $91.5M |
| Current Liabilities | $18.7M | $31.6M | $25.8M | $17.7M | $21.1M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $17.0M |
| Total Liabilities | $18.7M | $50.6M | $48.0M | $36.4M | $38.1M |
| Total Equity | $261.3M | $160.8M | $125.7M | $120.8M | $53.4M |
| Retained Earnings | -$91.7M | -$212.4M | -$286.2M | -$363.6M | -$443.2M |
Cash Flow (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$35.3M | -$89.3M | -$70.7M | -$57.7M | -$63.5M |
| Capital Expenditure | $-540,000 | -$6.4M | -$6.7M | $-237,000 | $-9,000 |
| Free Cash Flow | -$35.9M | -$95.7M | -$77.4M | -$57.9M | -$63.5M |
| Acquisitions (net) | $-50,000 | $0 | $6.7M | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $268.1M | -$95.6M | -$169.6M | $9.8M | -$4.1M |
Analyst Estimates (Annual)
| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$4.2M $4.2M – $4.2M
|
$13.8M $13.8M – $13.8M
|
$46.4M $46.4M – $46.4M
|
$115.2M $115.2M – $115.2M
|
| EBITDA |
$833,333 $833,333 – $833,333
|
$2.8M $2.8M – $2.8M
|
$9.3M $9.3M – $9.3M
|
$23.0M $23.0M – $23.0M
|
| Net Income |
-$83.4M -$107.9M – -$58.8M
|
-$115.9M -$121.8M – -$24.4M
|
-$62.4M -$62.4M – -$62.4M
|
-$39.2M -$39.2M – -$39.2M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | -14.2% |
| Gross Profit Growth | — | — | — | -26.8% |
| Operating Income Growth | -77.1% | +33.4% | -8.8% | +5.6% |
| Net Income Growth | -58.9% | +38.9% | -4.8% | -3.0% |
| EBITDA Growth | -77.8% | +34.6% | +18.4% | -22.0% |
No community reviews yet for PYXS.
Be the first — export the analysis to your AI and contribute back.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27